Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Camurus AB

Camurus AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)600.00
  • Today's Change2.00 / 0.33%
  • Shares traded25.63k
  • 1 Year change+76.99%
  • Beta0.9748
Data delayed at least 15 minutes, as of Nov 01 2024 12:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.

  • Revenue in SEK (TTM)1.59bn
  • Net income in SEK223.25m
  • Incorporated2004
  • Employees228.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Swedencare AB (publ)2.47bn76.20m7.36bn559.0096.570.95818.852.980.48010.480115.5848.390.24282.268.695,087,037.000.74831.380.77271.4356.7655.343.085.101.672.420.172645.3327.4888.16-37.9620.2430.90--
BioGaia AB1.36bn336.82m10.28bn222.0031.646.5925.207.583.333.3313.4216.010.6442----6,455,538.0016.0015.4717.7316.9373.5973.3024.8527.70----0.00104.4217.4411.81-2.2511.2029.2728.10
Bonesupport Holding AB814.46m90.58m22.04bn131.00245.8533.77218.0427.071.361.3612.299.921.160.61385.627,756,762.0012.85-9.0814.98-11.2892.4390.2511.12-11.653.50--0.0222--79.7643.65459.44--18.39--
Vimian Group AB4.08bn2.96m22.84bn1.10k8,858.772.9857.515.600.0050.0058.3214.790.34012.856.753,709,040.000.0938--0.1025--46.88--0.2758--2.182.060.2734--17.92--245.95------
Bavarian Nordic A/S9.45bn1.10bn26.29bn1.38k23.701.6112.982.789.069.0678.44133.680.41571.505.104,410,899.004.831.216.241.4856.9153.7211.634.060.9311--0.01180.00124.1469.78524.66--35.76--
Camurus AB1.59bn223.25m35.17bn228.00157.6611.97147.7322.073.793.7927.5149.940.61221.094.867,480,770.008.58-1.1310.10-1.4192.0190.0514.01-1.637.11--0.0071--79.52103.39676.63--16.29--
ALK-Abello A/S8.05bn1.07bn50.48bn2.81k51.877.2232.696.273.093.0922.9122.220.76731.276.111,834,278.0010.223.5012.564.3763.4260.6613.325.071.29479.500.09340.006.9410.6045.07--16.32--
Orion Oyj16.56bn3.84bn72.98bn3.82k18.946.7916.104.412.362.3610.166.580.95931.536.94393,502.2022.2519.4728.2524.1659.8959.3823.1920.711.41143.690.217491.83-11.264.01-37.971.8911.821.55
Swedish Orphan Biovitrum AB (publ)25.44bn3.51bn118.55bn1.81k33.113.0816.474.6610.0610.0672.98108.010.34431.375.7214,353,840.004.755.935.857.6078.6077.4213.8116.610.62254.350.3250.0017.7419.34-8.68-0.072953.61--
Data as of Nov 01 2024. Currency figures normalised to Camurus AB's reporting currency: Swedish Krona SEK

Institutional shareholders

18.04%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 May 20242.61m4.45%
Swedbank Robur Fonder ABas of 30 Sep 20241.95m3.33%
Handelsbanken Fonder ABas of 30 Sep 20241.42m2.42%
The Vanguard Group, Inc.as of 02 Oct 20241.14m1.94%
Norges Bank Investment Managementas of 30 Jun 2024700.35k1.19%
SEB Investment Management ABas of 30 Sep 2024625.22k1.07%
AFA Sjukf�rs�kringsaktiebolag (Invt Mgmt)as of 31 May 2024614.29k1.05%
Devon Equity Management Ltd.as of 30 Sep 2024589.48k1.01%
Baillie Gifford & Co.as of 30 Sep 2024484.98k0.83%
JPMorgan Asset Management (UK) Ltd.as of 30 Sep 2024447.85k0.76%
More ▼
Data from 30 Jun 2024 - 01 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.